Edition:
United States

Alexion Pharmaceuticals Inc (ALXN.O)

ALXN.O on Nasdaq

119.26USD
24 Mar 2017
Change (% chg)

-- (--)
Prev Close
$119.26
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,542,478
52-wk High
$162.00
52-wk Low
$109.12

Latest Key Developments (Source: Significant Developments)

Alexion reports Q2 non-gaap EPS $1.13
Thursday, 28 Jul 2016 06:30am EDT 

Alexion Pharmaceuticals Inc : Sees FY non gaap earnings per share $4.50 to $4.65 . Sees FY non gaap total revenues $3,050 to $3,100 million . FY2016 earnings per share view $5.05, revenue view $3.06 billion -- Thomson Reuters I/B/E/S . Alexion reports second quarter 2016 results . Q2 non-gaap earnings per share $1.13 . Q2 gaap earnings per share $0.51 . Q2 revenue $753 million versus I/B/E/S view $742.7 million . Q2 earnings per share view $1.17 -- Thomson Reuters I/B/E/S . Sees FY gaap earnings per share $1.91 to $2.26 .Sees FY gaap total revenues $3,050 to $3,100 million.  Full Article

Alexion Pharmaceuticals announces data from phase 1/2 study of ALXN1210
Friday, 10 Jun 2016 02:30am EDT 

Alexion Pharmaceuticals Inc : Late-Breaking data presented at EHA: all patients with pnh treated with once-monthly dosing of ALXN1210 in phase 1/2 study exhibit rapid and sustained reductions in ldhSays announced today that interim data were presented from a phase 1/2 study of ALXN1210 . Once-Monthly dosing of ALXN1210 achieved rapid and sustained reductions in mean levels of lactate dehydrogenase . Says no serious adverse events or study withdrawals were observed in either patient cohort . 2 patients experienced serious treatment-related adverse events and one patient had a grade 2 infusion-related reaction . Says six deaths were reported, none of which were considered related to treatment with ALXN1007 . Says were no grade 3 or higher non-serious adverse events related to treatment with ALXN1007 .Says one patient withdrew from study due to a treatment-emergent adverse event.  Full Article

Alexion announces topline results from Phase 3 regain study of eculizumab
Monday, 6 Jun 2016 04:01pm EDT 

Alexion Pharmaceuticals Inc : Alexion announces topline results from Phase 3 regain study of eculizumab (soliris) in patients with refractory generalized myasthenia gravis (GMG) . Primary endpoint of regain study missed statistical significance . Alexion continues to analyze data from regain study .Four patients receiving eculizumab (6.5 pct) discontinued treatment due to an adverse event.  Full Article

Alexion Pharmaceuticals says EC grants orphan drug designation to ALXN1210
Wednesday, 1 Jun 2016 04:05pm EDT 

Alexion Pharmaceuticals Inc :European Commission has granted orphan drug designation to ALXN1210.  Full Article

Alexion Pharmaceuticals Inc gives FY 2016 guidance
Wednesday, 3 Feb 2016 06:31am EST 

Alexion Pharmaceuticals Inc:Expects FY 2016 constant currency total product revenues of $3.170 to $3.220 billion.Expects FY 2016 constant currency earnings per share of $5.31 to $5.51.  Full Article

Alexion Pharmaceuticals Inc says NEJM publishes pivotal phase 3 data on Kanuma in children and adults with lysosomal acid lipase deficiency
Wednesday, 9 Sep 2015 05:00pm EDT 

Alexion Pharmaceuticals Inc:Says NEJM publishes pivotal phase 3 data on Kanuma in children and adults with lysosomal acid lipase deficiency.In the study, Kanuma met the primary endpoint of alanine aminotransferase normalization compared with placebo as well as six secondary endpoints.  Full Article

Alexion Pharmaceuticals Inc raises FY 2015 revenue guidance and lowers FY 2015 EPS guidance
Thursday, 30 Jul 2015 06:30am EDT 

Alexion Pharmaceuticals Inc:Raises FY 2015 revenue from the previous range of $2.55 to $2.6 billion to the higher and narrower range of $2.6 to $2.62 billion.Revises FY 2015 non-GAAP EPS guidance to the range of $4.70-$4.80 per share from the previous range of $5.60 to $5.80 per share.FY 2015 revenue of $2.63 billion and EPS of $4.98 - Thomson Reuters I/B/E/S.  Full Article

Alexion Pharmaceuticals Inc's Strensiq receives marketing approval in Japan
Monday, 6 Jul 2015 06:00am EDT 

Alexion Pharmaceuticals Inc:Says Japan's Ministry of Health, Labour and Welfare approves the Co's New Drug Applicatio for the use of Strensiq as a treatment for patients in Japan with hypophosphatasia (HPP).Expects that initial patients with HPP in Japan will start commercial treatment with Strensiq by late Q3 2015.  Full Article

Alexion Pharmaceuticals completes acquisition of Synageva
Tuesday, 23 Jun 2015 06:30am EDT 

Alexion Pharmaceuticals:Completed its previously announced acquisition of Synageva BioPharma Corp., strengthening its global leadership in devastating and rare diseases, and creating the most robust rare disease pipeline in the biotech industry across a range of therapeutic modalities.Transaction was completed through a merger of Synageva with and into a direct, wholly owned subsidiary of Alexion.  Full Article

Alexion Pharmaceuticals Inc will acquire Synageva BioPharma Corp
Wednesday, 6 May 2015 06:30am EDT 

Alexion Pharmaceuticals Inc and Synageva BioPharma Corp:Have entered into definitive agreement pursuant to which Alexion will acquire Synageva.Says acquisition for consideration of $115 in cash and 0.6581 Alexion shares, for each share of Synageva, implying a total per share value of $230 based on the nine day volume-weighted average closing price of Alexion stock through May 5.Says acquisition strengthens Alexion's global leadership in developing and commercializing transformative therapies for patients with devastating and rare diseases.  Full Article

More From Around the Web

BRIEF-Alexion submits application for soliris as treatment for refractory generalized myasthenia gravis

* Alexion submits application in Japan for soliris® (eculizumab) as a potential treatment for patients with refractory generalized myasthenia gravis (gmg) Source text for Eikon: Further company coverage: